Hikma Pharmaceuticals Share News (HIK)
HIK Share
HIK Share
HIK Share
HIK Share
HIK
HIK Share
HIK Level 2
HIK Live
HIK Broker
HIK Directors
HIK Financial
HIK
HIK Short
HIK
Last checked at -
Fri, 26th Aug 2016 11:13
LONDON (Alliance News) - Hikma Pharmaceuticals PLC Friday said Non-Executive Director Ronald Goode bought 2,000 shares at a price of 2,180 pence per share on Thursday
Following this transaction, Goode now holds 12,000 shares in the drugmaker.
The stock was up 1.2% at 2,176.00p Friday.
By Arvind Bhunjun; arvindbhunjun@alliancenews.com; @ArvindBhunjun
Copyright 2016 Alliance News Limited. All Rights Reserved.
(Sharecast News) - Bio-Thera Solutions and Hikma Pharmaceuticals have entered into a commercialisation and license agreement to commercialise a monoclonal antibody used for the treatment of Crohn's disease.
Read moreLONDON BROKER RATINGS: Peel Hunt ups InterContinental Hotels to Hold
Read moreLONDON BRIEFING: Softbank's Fortress doesn't give up on Morrisons
Read more
(For a Reuters live blog on U.S., UK and European stock markets, click LIVE/ or type LIVE/ in a news window)* UK employment closer to pre-pandemic levels* BHP Group jumps on strong results* PLUS500 gains on robust revenue forecasts* FTSE 100 up 0.3%...
Read moreLONDON MARKET CLOSE: FTSE 100 boosted by strong US jobs report
Read moreLONDON MARKET MIDDAY: Caution dominates ahead of US nonfarm payrolls
Read moreLONDON MARKET OPEN: Stocks soft, dollar up as US nonfarm payrolls near
Read moreTOP NEWS: Hikma hikes Generics guidance as interim profit swells
Read moreLONDON MARKET PRE-OPEN: LSEG raises Refinitiv cost synergy guidance
Read more(Sharecast News) - Hikma Pharmaceuticals upgraded full-year guidance for its generics arm and reported a rise in first-half profit and revenue as it hailed a strong performance in both the generics and branded segments, and resilience in the injectables business.
Read moreUK earnings, trading statements calendar - next 7 days
Read moreIN BRIEF: Arecor ends first half of 2021 with solid cash position
Read moreBROKER RATINGS: Barclays upgrades Shell and EnQuest to Overweight
Read moreBROKER RATINGS: Credit Suisse upgrades Legal & General and StanChart
Read more
Last checked at